低位直肠癌保肛术后应用艾恒为主联合化疗的临床研究  

A Clinic Trial of Ai-Heng and Sphincter-saving Resection for Distal Rectal Cancer

作　　者：詹洪峰[1] 契燕燕[1] 刘书琴[1] 

机构地区：[1]江苏大学附属人民医院肿瘤科,镇江212002

出　　处：《齐齐哈尔医学院学报》2005年第2期129-130,共2页Journal of Qiqihar Medical University

摘　　要：目的　观察以艾恒为主的联合化疗治疗直肠癌保肛术后患者的疗效及副作用。方法　低位直肠癌保肛后患者38例,分为2组,对照组16例,保肛手术后用传统化疗方案(5FU+CF)化疗 6 个周期;艾恒组22例,在传统化疗方案上加用艾恒。观察两者疗效及毒副作用。结果　艾恒组有效率和3年存活率均明显高于对照组,复发率明显低于对照组,两者之间有显著性差异(P <0.05)。化疗副作用较轻。结论　艾恒与氟脲嘧啶及甲酰四氢叶酸的联合应用是治疗低位直肠癌保肛术后较理想的治疗方案,值得临床进一步推广应用。Objective To study the response rate and the side effect of Ai-Heng and sphincter-saving resection for distal rectal cancer. Methods 38 patients of distal rectal cancer after sphincter-saving resection were divided into 2 groups: in control group,16 patients were enrolled six course chemotherapy with 5FU and CF; in Ai-Heng group,22 patients were enrolled six course chemotherapy with Ai-Heng, 5FU and CF. To study the response rate and the side effect of two groups. Results The response rate and three year survival rate of Ai-Heng group were higher than control group, while the recurrence rate of Ai-Heng group were lower, there were significant differences in two groups (P<0.05). The side effect of Ai-Heng was well tolerated.Conclusions Ai-Heng combined with 5FU/CF is a very effective regimen for the treatment of distal cancer after sphincter saving resection, and it is worthy of being further investigated.

关 键 词：直肠癌保肛 艾恒 临床研究 联合化疗 术后应用 疗效及副作用 甲酰四氢叶酸 化疗方案 显著性差异 化疗副作用 低位直肠癌 对照组 术后患者 化疗治疗 毒副作用 治疗方案 保肛术后 氟脲嘧啶 推广应用 手术后 复发率 存活率 

分 类 号：R473.73[医药卫生—护理学] R730.53[医药卫生—临床医学]